Hazem E. Mohammed

Hazem E. Mohammed

Auto-generated profile, based on publicly available information

Hazem E. Mohammed

Faculty of Medicine, Assiut University, Assiut, Egypt

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Head & Face Medicine
Verified
Journal Article
Open access
PDF file
MHMohamed E. Haseeb
Mohamed E. Haseeb
HMHazem E. Mohammed
Hazem E. Mohammed
HYHatem Yaser
Hatem Yaser
GHGeorge Hanen
George Hanen
MNMohamed Nasser
Mohamed Nasser
ZBZeyad Bady
Zeyad Bady
Background: Migraine is a highly prevalent and disabling disease, affecting nearly 14% of the global population. Preventive medications involve drugs like beta-adrenergic blockers, antidepressants, and anticonvulsants. However, these drugs lacked effectiveness, and patients showed poor tolerance and low adherence to them. Erenumab, a calcitonin gene-related peptide receptor blocker, has recently shown promising results in migraine management. In this meta-analysis, the efficacy of Erenumab is investigated by employing a subgroup analysis approach. Methods: We conducted a systematic search of six electronic databases until July 2024. Review Manager 5.4 software was utilized for the analysis, based on either weighted mean difference (MD) and standard deviation (SD) for continuous outcomes or risk ratio (RR) for dichotomous outcomes, with a confidence interval (CI) of 95%. A P-value < 0.05 indicated statistical significance. The study was registered on PROSPERO with registration number CRD42024573300. Additionally, we conducted subgroup analyses and assessed the quality of evidence using GRADE. Results: A total of 20 randomized controlled trials (n = 5212) were included in our analysis. At three months, Erenumab showed statistically significant improvements in monthly migraine days (MMD), monthly acute migraine-specific medication days (MSMD), Headache Impact Test (HIT-6) score, and ≥ 50% reduction from baseline in MMD (MD: -1.78, 95% CI: [-2.37 to -1.20], P < 0.00001), (MD: -1.36, 95% CI: [-1.92 to -0.81], P < 0.00001), (MD: -2.83, 95% CI: [-3.83 to -1.82], P < 0.00001), and (RR: 1.52, 95% CI: [1.31 to 1.76], P < 0.00001), respectively. Subgroup analysis revealed that Erenumab was significantly more effective in patients with prior preventive treatment failures compared to patients with no prior failure. No significant difference in Erenumab`s response existed between episodic and chronic migraine or between 140 and 70 mg, except for MSMD in dose subgrouping. Only constipation emerged as a significant adverse effect in the Erenumab group. Conclusions: This meta-analysis found that Erenumab significantly reduced migraine attack frequency, medication days, and physical impairment. It was more effective for patients with prior treatment failures. The 140 mg dose showed better MSMD reduction than 70 mg. Erenumab's safety profile was similar to that of placebo, with only constipation noted as significant.

31 March 2025 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
HMHazem E. Mohammed
Hazem E. Mohammed
MGMenna A. Gomaa
Menna A. Gomaa
YKYoussef Magdy Khalifa
Youssef Magdy Khalifa
ASAhmed Ayman Shawky
Ahmed Ayman Shawky
Background: Schizophrenia is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms. KarXT, a novel combination of xanomeline and trospium, offers potential therapeutic benefits for schizophrenia treatment by targeting muscarinic receptors and avoiding dopamine receptor blockade. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of KarXT. Methods: PubMed, Scopus, Web of Science, and Cochrane databases were systematically searched for relevant randomized controlled trials (RCTs) up to October 2024. Studies involving adult patients with schizophrenia treated with KarXT were included. Furthermore, the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was used to assess evidence quality, and the risk of bias was evaluated using the Cochrane Risk of Bias 2.0 tool. Results: Four studies with 690 participants were included. KarXT significantly reduced Positive and Negative Syndrome Scale (PANSS) total scores compared to placebo (mean difference (MD): -13.77, 95% confidence interval (CI) [-22.33 to -5.20], P-value = 0.002), with significant improvements in positive and negative subscale scores. It significantly increased the incidence of achieving ≥ 30% PANSS score reduction (risk ratio: 2.15, 95% CI [1.64 to 2.84], P < 0.00001). Moreover, KarXT demonstrated a favorable safety profile, with side effects such as nausea and constipation being mild and transient. Notably, it was not significantly associated with weight gain or extrapyramidal symptoms, which are common with traditional antipsychotics. Conclusions: KarXT’s distinct mechanism and tolerability highlight its potential to address unmet needs in schizophrenia treatment. Future studies should explore its long-term efficacy, delayed adverse effects, and comparative effectiveness against existing therapies. Clinical trial number: Not applicable.

8 July 2025 in Neurocritical Care
Verified
Journal Article
Open access
PDF file
HMHazem E. Mohammed
Hazem E. Mohammed
MHMohamed E. Haseeb
Mohamed E. Haseeb
ZBZeyad Bady
Zeyad Bady
MNMohamed Nasser
Mohamed Nasser
MMMostafa Mahmoud Meshref
Mostafa Mahmoud Meshref
Background: Stroke is a significant cause of morbidity and mortality worldwide, with cerebral edema being a major complication. Glibenclamide, a SUR1-TRPM4 channel inhibitor, has been proposed to reduce cerebral edema, but its clinical efficacy remains uncertain. This meta-analysis aimed to evaluate the efficacy and safety of glibenclamide in patients with stroke, including acute ischemic stroke, acute subarachnoid hemorrhage, and intracerebral hemorrhage. Methods: A comprehensive literature search was conducted in PubMed, Web of Science, and Scopus up to January 2025. The primary efficacy outcomes included excellent (modified Rankin Scale [mRS] score 0–1) and good (mRS score 0–2) functional outcomes at 90 days. Safety outcomes included the incidence of hypoglycemia and decompressive craniectomy. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach. Results: Ten and eight randomized controlled trials (RCTs) were included in our qualitative and quantitative analysis, respectively, encompassing 1,691 participants aged 18 to 85. No significant difference was observed between the glibenclamide and control groups regarding excellent functional outcome (risk ratio [RR] 1.10, 95% confidence interval [CI] 0.92–1.32, P = 0.29) and good functional outcome (RR 1.07, 95% CI 0.96–1.18, P = 0.22). Safety analysis revealed no significant increase in serious adverse events (RR 1.11, 95% CI 1.00–1.23, P = 0.06). Notably, hypoglycemia incidence after sensitivity analysis was higher in the glibenclamide group (RR 4.56, 95% CI 2.07–10.03, P = 0.0002). Conclusions: Glibenclamide did not significantly improve functional outcomes or reduce mortality in stroke patients but was associated with a higher incidence of hypoglycemia. Further well-designed RCTs are needed to clarify its therapeutic role and optimize safety protocols. Clinical trial registration : PROSPERO registration number: CRD420251008350.


12 August 2025 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
GHGeorge Hanen
George Hanen
HMHazem E. Mohammed
Hazem E. Mohammed
MNMohamed Nasser
Mohamed Nasser
MHMohamed E. Haseeb
Mohamed E. Haseeb
HYHatem Yaser
Hatem Yaser
SASalma Allam
Salma Allam
Purpose: Lynch syndrome patients are at a high risk for developing colorectal cancer; thus, optimal surveillance strategies are required. Although colonoscopic imaging methods differ in diagnostic performance, direct comparisons in this population are not very common. We aimed to evaluate and compare the detection capabilities of white-light endoscopy (WLE), chromoendoscopy, virtual chromoendoscopy (NBI: narrow band imaging, LCI: linked color imaging, I-SCAN), and AI-assisted colonoscopy in detecting neoplastic and non-neoplastic lesions in individuals diagnosed with Lynch syndrome. Methods: Up until March 2025, PubMed, WOS, and Scopus were searched. Relevant studies included observational or interventional designs that contrasted various forms of colonoscopy in adults with Lynch syndrome. The primary outcomes were the lesion detection rate and number of lesions per colonoscopy. Secondary outcomes included total procedure time and withdrawal time. Credibility of the evidence was assessed employing CINeMA. Results: Nine studies were included. LCI and chromoendoscopy demonstrated a significantly higher neoplastic lesion detection rate compared to WLE (RD 0.11, 95% CI [0.01, 0.21], P = 0.03) and (RD 0.07, 95% CI [0.01, 0.14], P = 0.03), respectively, and LCI significantly detected more lesions per procedure (MD = 0.23, 95% CI 0.01–0.45, P = 0.04). Chromoendoscopy was better at marking the non-neoplastic lesions (RD 0.16, 95% CI [0.05, 0.27], P = 0.005) but had the longest procedure and withdrawal times. AI-assisted, as well as virtual ones, were better than WLE but were not as effective as LCI or chromoendoscopy. Conclusion: In terms of efficiency, LCI and chromoendoscopy improved WLE in detecting neoplastic lesions in Lynch syndrome. Chromoendoscopy remains valuable for non-neoplastic detection, but procedural time is a major drawback. AI-assisted technologies are promising, which require additional investigation.

26 August 2025 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
MNMohamed Nasser
Mohamed Nasser
HMHazem E. Mohammed
Hazem E. Mohammed
MHMohamed E. Haseeb
Mohamed E. Haseeb
MDMohamed Khalafalla Darwish
Mohamed Khalafalla Darwish
GHGeorge Hanen
George Hanen
MAMohamed Salem Abdelkader
Mohamed Salem Abdelkader
Purpose: Homozygous Familial Hypercholesterolemia (HoFH) is a rare and life-threatening genetic disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and early-onset atherosclerotic cardiovascular disease. Lomitapide, a microsomal triglyceride transfer protein (MTP) inhibitor, decreases LDL-C independent of LDL receptor function, providing an alternative treatment in this population. We aimed to evaluate the efficacy and safety of lomitapide in patients with HoFH through a systematic review and meta-analysis of available clinical evidence. Methods: A comprehensive search was conducted in PubMed, Scopus, and Web of Science through March 2025. Observational studies and clinical trials reporting on lipid profile changes and safety outcomes in HoFH patients receiving lomitapide were included. Outcomes were pooled using random-effects models, and heterogeneity was assessed using the I 2 statistic. Results: Eight studies comprising both adult and pediatric patients (n = 209) were included. Lomitapide significantly reduced LDL-C levels by 49.27%, total cholesterol by 46.05%, and apolipoprotein B by 51.01%. Reductions were also observed in triglycerides, VLDL-C, and non–HDL-C. HDL-C remained relatively unchanged. Adverse events were mostly gastrointestinal, with a 14% discontinuation rate. The overall quality of studies ranged from fair to good. Conclusions: Lomitapide demonstrates substantial efficacy in reducing LDL-C and other atherogenic lipids in HoFH patients, with an acceptable safety profile. These findings support its role as an adjunctive therapy in this population, though further randomized controlled trials are warranted to validate long-term safety and effectiveness.